Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
AML
•
Hematology
Do you prefer quizartinib over midostaurin with chemotherapy induction for FLT3-ITD mutated AML given the results of QUANTUM-FIRST and preclinical advantages over other FLT3 inhibitors?
Related Questions
What is your current approach to maintenance therapy in FLT3-mutant AML post allogeneic HCT?
How has your approach to utilizing MRD-guided therapy in previously untreated CLL changed since the FLAIR trial, particularly in choosing between continuous versus time-limited treatment?
Would you re challenge a CLL patient, who had good response to Zanubrutinib but contracted cryptococcal pneumonia, with another TKI?
Do complex cytogenetics have any therapeutic or prognostic relevance in CLL?
How should one approach an incidentally found T-cell gene arrangement?
Is it possible to give Inotuzumab ozogamicin in the front line setting for an older patient with Ph- Pre-B-ALL?
Do you prefer to use 7+3 or CPX-351 as standard induction therapy in younger patients with AML-MRC or t-AML?
How would you manage an elderly patient with mild pancytopenia who refuses bone marrow biopsy and whose flow cytometry is suggestive of CMML/MDS?
How long do you continue ATRA during induction in high risk acute promyelocytic leukemia?
For AML patients, when do you stop antiinfective agents?
